Compare Diageo plc (DEO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs TG Therapeutics Inc — how do they compare? Diageo plc trades at $86.83 (market cap $47.67B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Diageo plc is far larger — about 5.8× TG Therapeutics Inc's market cap, and Diageo plc pays a 2.3% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and TG Therapeutics Inc for 16 Days on average.
| DEO | TGTX | |
|---|---|---|
Market Cap | $47.67B | $8.16B |
Volume | 893,372 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $59.06 |
52-Week Low | $72.47 | $26.94 |
Typical Hold Time | 66 Days | 16 Days |
Enterprise Value | $68.09B | $8.37B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.73, up 2.36% with bullish technical signals from moving averages. The company shows strong profitability with 59.47% gross margins and has beaten earnings estimates in the last three quarters. Recent developments include a new CFO appointment and marketing initiatives across key brands. The stock faces headwinds from declining 2026 revenue projections but maintains solid cash flow generation.
DEO presents a mixed outlook with analyst consensus leaning bullish (49% buy ratings) but facing execution risks in its US turnaround. The stock's premium valuation (P/E 27.9) requires sustained earnings growth, while regulatory challenges in India and competitive pressures warrant monitoring. Near-term catalysts include dividend payments and brand revitalization efforts.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
